ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RIGL Rigel Pharmaceuticals Inc

1.22
0.07 (6.09%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Rigel Pharmaceuticals Inc NASDAQ:RIGL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.07 6.09% 1.22 1.16 1.26 1.22 1.16 1.18 791,587 01:00:00

Rigel Announces Conference Call and Webcast to Report Second Quarter 2016 Financial Results

26/07/2016 12:30pm

PR Newswire (US)


Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Rigel Pharmaceuticals Charts.

SOUTH SAN FRANCISCO, Calif., July 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2016 financial results after market close on Tuesday, August 2, 2016.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 54498109.  The conference call will also be webcast live and can be accessed from Rigel's website at www.rigel.com.  The webcast will be archived and available for replay after the call via the Rigel website.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com

Rigel Pharmaceuticals, Inc.

Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2016-financial-results-300303623.html

SOURCE Rigel Pharmaceuticals, Inc.

Copyright 2016 PR Newswire

1 Year Rigel Pharmaceuticals Chart

1 Year Rigel Pharmaceuticals Chart

1 Month Rigel Pharmaceuticals Chart

1 Month Rigel Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock